Search

Displaying results 2401 - 2410 of 10000 in total
  1. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    It is a structural analog of [doxepin], which has a minimal anti-allergic activity. … [A1172] In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes.

    Products: OLO-A-DAY, Pataday Twice A Day Relief
  2. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    Nipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker used to treat certain antibody-mediated autoimmune diseases. … [L64042] This reduction in autoantibodies underlies its therapeutic effect across autoantibody-driven conditions.[L64042] It is administered by intravenous infusion.

  3. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may … Abametapir is a novel pediculicidal metalloproteinase inhibitor used to treat infestations of head lice.

  4. Drug

    Eucalyptol

    go.drugbank.com/drugs/DB03852
    ApprovedInvestigationalNutraceutical

    It kills leukaemia cells in vitro. … Eucalyptol is naturally produced cyclic ether and monoterpenoid. Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant.

    Mixtures: Demo Cineol InjCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    [L64050,L64051] The approval covers adults and pediatric patients 8 years of age and older and was based on a statistically significant reduction in daily cornstarch intake, a surrogate endpoint, with … [L64050,L64051] It delivers a functional copy of the human G6PC gene, under the control of native G6PC promoter and enhancer elements, to hepatocytes, resulting in the production of normally functioning

  6. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    [L8336,L8339] On a weight basis, methimazole is 10 times more potent than the other major antithyroid thionamide used in North America, [propylthiouracil],[L8339] and is the active metabolite of the … Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.

  7. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008. … It gained approval by European Commission in March 2009.

  8. Drug

    Nicoboxil

    go.drugbank.com/drugs/DB12911
    ApprovedWithdrawn

    Nevertheless, it is predominantly found paired with nonivamide as a combination topical analgesic product where its proposed mechanism of action as a rubefacient is complementary and ultimately synergistic … Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16].

  9. Drug

    Isopropyl myristate

    go.drugbank.com/drugs/DB13966
    Approved

    Isopropyl myristate is a moisturizer with polar characteristics used in cosmetics and topical medical preparations to ameliorate the skin absorption. … [A178078] At the moment the primary usage for which isopropyl myristate is formally indicated is as the active ingredient in a non-prescription pediculicide rinse [A32333, L1964, L1966].

  10. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors. … [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor